Want to see AU:RAC full AI Analyst Report?
RAC Stock Chart & Stats
AU$2.12
AU$0.02(0.98%)
At close: 4:00 PM EDT
AU$2.12
AU$0.02(0.98%)
Day’s Range― - ―
52-Week RangeAU$1.53 - AU$3.90
Previous CloseN/A
Volume42.13K
Average Volume (3M)82.50K
Market Cap
AU$311.75M
Enterprise ValueAU$367.74M
Total Cash (Recent Filing)AU$34.29M
Total Debt (Recent Filing)AU$0.00
Price to Earnings (P/E)―
Beta0.16
Next Earnings
Mar 03, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.06
Shares Outstanding196,068,940
10 Day Avg. Volume82,621
30 Day Avg. Volume82,504
Financial Highlights & Ratios
PEG Ratio-0.29
Price to Book (P/B)10.91
Price to Sales (P/S)0.00
P/FCF Ratio-48.21
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.1
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Debt-Free Balance SheetA debt-free structure removes scheduled debt service and lowers solvency pressure, giving the company more flexibility to direct available capital toward clinical development. However, this strength is financial resilience rather than evidence that operations are self-funding.
Prior Revenue GrowthRevenue grew about 51% in FY2025 and 28% in FY2024, showing the business had previously demonstrated commercial momentum. That history offers a base to rebuild from, although FY2026’s zero revenue means the trend has not yet proved durable.
Focused Oncology PipelineThe company is focused on oncology therapeutics and has a lead program repurposing bisantrene, alongside combination-treatment research and clinical planning. This concentrated development strategy can focus scarce resources, while approval and commercialisation remain future goals.
Bears Say
Revenue CollapseFY2026 revenue fell to zero after growth in earlier years, marking a severe break in operating momentum. Without current revenue contribution, the company has limited demonstrated commercial traction and must rely on development progress to rebuild a recurring business base.
Persistent Cash BurnSustained negative operating and free cash flow shows that the business is not currently funding itself through operations. Continued cash burn can require external funding unless revenue ramps materially, potentially limiting development pace and increasing financing dependence.
Recurring Losses And Negative ReturnsPersistent operating and net losses, combined with negative returns on equity, indicate that the company has not yet established a profitable economic model. This weak value creation can constrain reinvestment capacity and sustain dilution or earnings-drag risk.
Race Oncology Ltd. News
RAC FAQ
What was Race Oncology Ltd.’s price range in the past 12 months?
Race Oncology Ltd. lowest share price was AU$1.53 and its highest was AU$3.90 in the past 12 months.
What is Race Oncology Ltd.’s market cap?
Race Oncology Ltd.’s market cap is AU$311.75M.
When is Race Oncology Ltd.’s upcoming earnings report date?
Race Oncology Ltd.’s upcoming earnings report date is Mar 03, 2027 which is in 131 days.
How were Race Oncology Ltd.’s earnings last quarter?
Race Oncology Ltd. released its earnings results on Aug 25, 2026. The company reported -AU$0.039 earnings per share for the quarter.
Is Race Oncology Ltd. overvalued?
According to Wall Street analysts Race Oncology Ltd.’s price is currently Overvalued.
Does Race Oncology Ltd. pay dividends?
Race Oncology Ltd. does not currently pay dividends.
What is Race Oncology Ltd.’s EPS estimate?
Race Oncology Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Race Oncology Ltd. have?
Race Oncology Ltd. has 196,068,940 shares outstanding.
What happened to Race Oncology Ltd.’s price movement after its last earnings report?
Race Oncology Ltd. reported an EPS of -AU$0.039 in its last earnings report. Following the earnings report the stock price went up 0.952%.
Which hedge fund is a major shareholder of Race Oncology Ltd.?
Currently, no hedge funds are holding shares in AU:RAC
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Race Oncology Ltd. Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Bullish
AU:RAC Sentiment 95%
Sector Average 66%
Sector Average 66%
Insider Transactions
Bought Shares
Worth AU$35.7K over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-60.90%
12-Months-Change
Fundamentals
Return on Equity
-36.95%
Trailing 12-Months
Asset Growth
117.78%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Race Oncology Ltd.
Headquartered in Sydney, Australia, Race Oncology Limited is a precision oncology company focused on advancing its lead therapeutic, Zantrene. This potent small molecule compound acts as an inhibitor of the fatso/fat mass and obesity associated protein (FTO) and is currently undergoing Phase II/III clinical trials. Zantrene is being investigated for its potential to treat a range of cancers, including melanoma, clear cell renal cell carcinoma, acute myeloid leukaemia, breast cancer, and ovarian cancer. The company maintains an active preclinical research program with the University of Newcastle, focusing on Zantrene, and has also forged a strategic alliance with the University of Wollongong to assess various formulations of the drug. Established in 2011, Race Oncology Limited adopted its current name in July 2016, having previously operated as Coronado Resources Limited.
Technical Analysis
Imugene
―
Immutep Ltd
―
Telix Pharmaceuticals
―
Clarity Pharmaceuticals Ltd.
―
Radiopharm Theranostics Limited
―